Last reviewed · How we verify
PWT33597 mesylate — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PWT33597 mesylate (PWT33597 mesylate) — Pathway Therapeutics, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PWT33597 mesylate TARGET | PWT33597 mesylate | Pathway Therapeutics, Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PWT33597 mesylate CI watch — RSS
- PWT33597 mesylate CI watch — Atom
- PWT33597 mesylate CI watch — JSON
- PWT33597 mesylate alone — RSS
Cite this brief
Drug Landscape (2026). PWT33597 mesylate — Competitive Intelligence Brief. https://druglandscape.com/ci/pwt33597-mesylate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing